American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Latest News

Novo Nordisk CEO to step down as obesity drug competition intensifies

by admin May 18, 2025
May 18, 2025
Novo Nordisk CEO to step down as obesity drug competition intensifies

Novo Nordisk said on Friday that Chief Executive Officer Lars Fruergaard Jørgensen will step down, a decision made jointly with the board as the company confronts mounting competitive and financial pressures.

The changes are being made “in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024,” the company said.

The Danish drugmaker said Jørgensen would remain in place “for a period” to help ensure a smooth leadership transition.

A formal search for his successor is underway, with an announcement expected in due course.

Jørgensen’s departure comes at a time when the company’s performance has been under scrutiny.

Shares in the pharmaceutical firm fell by more than 4% following the announcement in Copenhagen, while its US-listed stock dropped 5.61% in premarket trading.

The company’s shares have lost more than 24% of their value so far this year in the US, and close to 35% in Copenhagen.

Meanwhile, Eli Lilly has lost only about 5.8% YTD. Its share price was up by 1.36% in pre-market trading.

In a statement, Novo Nordisk said the decision was the result of internal discussions initiated by the Novo Nordisk Foundation, which considered the merits of accelerating CEO succession.

“Novo Nordisk’s strategy remains unchanged, and the Board is confident in the company’s current business plans and its ability to execute on the plans,” said Chairman Helge Lund.

Jørgensen’s tenure saw early success of Wegovy, Ozempic before Eli Lilly took over

Jørgensen has been with Novo Nordisk since 1991 and took over as CEO in 2017.

Under his leadership, the company cemented its lead in the growing global market for obesity and diabetes treatments, largely thanks to the success of Wegovy and Ozempic.

These drugs contributed to soaring sales and investor enthusiasm, turning Novo Nordisk into one of Europe’s most valuable companies.

However, recent developments have rattled investor confidence.

Eli Lilly’s obesity drug Zepbound has steadily gained traction in the United States, surpassing Wegovy in prescriptions since mid-March.

Meanwhile, results from Novo’s trials for next-generation obesity treatments have fallen short of expectations, casting doubts over the company’s future product pipeline.

Strategic partnerships to defend market share

In response to the competitive threat, Novo Nordisk has pursued several strategic partnerships.

Just a day before the CEO announcement, the company signed a collaboration agreement with biotech firm Septerna, potentially worth up to $2.2 billion.

The partnership aims to discover up to four new obesity therapies, with Septerna eligible for over $200 million in upfront and near-term payments.

Novo has also sought to expand access to its existing treatments through US telehealth firms like Hims & Hers, Ro, and LifeMD.

These partnerships allow for direct-to-patient distribution of Wegovy in the US, amid tighter regulations on compounding pharmacies that previously filled the gap during drug shortages.

Despite these efforts, the CEO transition marks a critical moment for Novo Nordisk as it navigates a more crowded and aggressive market landscape.

The post Novo Nordisk CEO to step down as obesity drug competition intensifies appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Argentina’s black market for dollar falters as President Milei dismantles currency controls
next post
Rich List 2025: UK billionaires decline for first time in years amid market turmoil

Related Posts

Giant oddball planet has the density of fluffy...

May 18, 2024

Ukraine claims Russian forces using Starlink network in...

February 13, 2024

Taylor Swift endorses Kamala Harris: Can the singer’s...

September 11, 2024

The Princess of Wales controversy has only gotten...

March 16, 2024

How long will your dog live? Measure its...

February 4, 2024

Attack kills 20 and injures 155 at Gaza...

March 16, 2024

The US allowed a Gaza ceasefire resolution to...

March 28, 2024

Why is Honeywell splitting into three companies?

February 7, 2025

Burger King UK seeks £40M refinancing to fund...

March 20, 2025

The conman, his lovers and the mother who...

March 3, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • How Donald Trump’s immigration crackdown may tank the labor market

      August 4, 2025
    • Trump’s tariff threat looms over India’s Russian oil deals

      August 4, 2025
    • Trump moves nuclear submarines near Russia: what triggered the move and what’s ahead

      August 3, 2025
    • BOE rate cuts offer little relief as UK households face mounting financial strain

      August 3, 2025
    • Retail investors shift focus to Europe as US valuations stretch

      August 3, 2025

    Categories

    • Business (3,612)
    • Investing (2,713)
    • Latest News (2,031)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved